Pharmacogenetics of Nicotine Addiction Treatment

Status Completed

Clinical Trial Summary

The purpose of this research program is to understand how a biomarker called the "nicotine metabolite ratio" (also referred to as NMR) may influence a smoker's ability to quit smoking.

Clinical Trial Description

Smoking is an enormous public health problem with a great need for research to improve treatment outcomes. Our prior data indicates that the cytochrome P450 2A6 (CYP2A6) enzyme is critical in the metabolic inactivation of nicotine, and also influences smoking behavior and response to therapies. With a vision toward translation of our research to practice, we have characterized a genetically-informed biomarker of CYP2A6 activity, specifically the nicotine metabolite ratio (NMR; 3'hydroxycotinine/cotinine), which reflects both CYP2A6 genetic variation and environmental influences on CYP2A6 activity. The NMR is measured non-invasively in smokers with established reliability, stability, analytic validity, and efficacy as a predictor of the ability to quit smoking and treatment response in multiple retrospective trials. Translation of these findings to clinical practice requires validation in a prospective clinical trial comparing alternative therapies for smoking cessation. Thus, the proposed trial is a prospective, stratified, placebo-controlled, multi-center clinical trial of alternative therapies for smoking cessation treatment in approximately 1,200 smokers. Randomization to placebo (PLA), transdermal nicotine (TN), or varenicline (VAR) will be stratified prospectively based on the nicotine metabolite ratio (NMR). Abstinence from smoking at the end of treatment will be the primary outcome. Quit rate at 6-month follow-up is a secondary outcome. To facilitate translation to practice, analysis of the cost-effectiveness of our proposed approach will also be completed. The proposed research provides the next critical step to validate a genetically-informed diagnostic tool, the NMR, which clinicians can use in the future to optimize treatment decisions for their patients who wish to quit smoking. ;

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01314001
Study type	Interventional
Source	University of Pennsylvania
Contact
Status	Completed
Phase	Phase 3
Start date	December 2010
Completion date	September 2014

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT02643914` - Control Systems Approach to Predicting Individualized Dynamics of Nicotine Cravings	N/A
Completed	`NCT02153749` - Effects of Brief Training on Craving Regulation	N/A
Recruiting	`NCT05530577` - Effects of Semaglutide on Nicotine Intake	Phase 2
Withdrawn	`NCT05440721` - Clinical Trial of an Innovative Digital Therapeutic for Smoking Cessation With Biochemical Verification	N/A
Completed	`NCT03694327` - Innovative Digital Therapeutic for Smoking Cessation	N/A
Completed	`NCT01944423` - Enhancing Panic and Smoking Reduction Treatment With D-Cycloserine	Early Phase 1
Completed	`NCT01704573` - Nicotinic Receptor Levels After Stopping Smoking	N/A
Active, not recruiting	`NCT01015170` - STOP Study: Effectiveness of Zyban in a Clinical Population	Phase 4
Completed	`NCT03281629` - Circuitry-Guided Smoking Cessation in Schizophrenia	N/A
Recruiting	`NCT06291584` - Effects of Exercises on Functional Capacity	N/A
Withdrawn	`NCT06259630` - Nicotine Virtual Reality Conditioned Place Preference	Phase 4
Completed	`NCT02624284` - tDCS Effects on Resisting Smoking: Dose Ranging Study	N/A
Active, not recruiting	`NCT02837510` - Neural Mechanisms Associated With Risk of Smoking Relapse	N/A
Completed	`NCT02656745` - Clinical Trial of Smoking Cessation Mobile Phone Program	N/A
Completed	`NCT01062932` - Investigation of Cycloserine as a Smoking Cessation Treatment	Phase 1
Completed	`NCT03069482` - Feasibility Trial of a Tailored Smoking Cessation App for People With Serious Mental Illness	Phase 1
Completed	`NCT02870218` - Abuse Liability of Reduced Nicotine Content Cigarettes in the Context of Concurrent E-Cigarette Use	Phase 2
Terminated	`NCT01756053` - Effects of ABT-089 on Smoking Abstinence Symptoms and Reward	Phase 2
Completed	`NCT01252966` - Cognitive Training for Nicotine Dependence	N/A
Active, not recruiting	`NCT04946825` - Quit Smoking Study for People Who Use E-Cigarettes	Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.